These findings should be considered in conjunction with therapeutic strategies under current investigation, using B-RAF and N-RAS as molecular targets [22], e.g. considering the observation that inhibitors of N-RAS like farnesyltransferase inhibitors might not be effective in melanoma therapy [23]. Here, BRAF is linked to melanoma.